ReP USP - Resultado da busca

Artigo de periodico
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial (2021)
Tardif, Jean-Claude; Bouabdallaoui, Nadia; L'allier, Philippe L; Gaudet, Daniel; Shah, Binita; Pillinger, Michael H; Lopez-Sendon, Jose; Luz, Protásio Lemos da ; Verret, Lucie; Audet, Sylvia
Source: Lancet respiratory medicine. Unidade: FM
Subjects: COVID-19, INFLAMAÇÃO, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TARDIF, Jean-Claude et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, v. 9, n. 8, p. 924-932, 2021Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(21)00222-8. Acesso em: 12 nov. 2024.
APA
Tardif, J. -C., Bouabdallaoui, N., L'allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., et al. (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, 9( 8), 924-932. doi:10.1016/S2213-2600(21)00222-8
NLM
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8
Vancouver
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8
Artigo de periodico
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab (2018)
Ridker, Paul M.; Santos Filho, Raul Dias dos; Rose, Lynda M; Kastelein, John J. P; Wei, Caimiao; Revkin, James; YUNIS, Carla; Tardif, Jean-Claude; Shear, Charles L
Source: Journal of clinical lipidology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS GENÉTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, v. 12, n. 4, p. 958-965, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2018.03.088. Acesso em: 12 nov. 2024.
APA
Ridker, P. M., Santos Filho, R. D. dos, Rose, L. M., Kastelein, J. J. P., Wei, C., Revkin, J., et al. (2018). Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. Journal of clinical lipidology, 12( 4), 958-965. doi:10.1016/j.jacl.2018.03.088
NLM
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088
Vancouver
Ridker PM, Santos Filho RD dos, Rose LM, Kastelein JJP, Wei C, Revkin J, YUNIS C, Tardif J-C, Shear CL. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab [Internet]. Journal of clinical lipidology. 2018 ; 12( 4): 958-965.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1016/j.jacl.2018.03.088
Artigo de periodico
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (2017)
Ridker, Paul M.; Revkin, James; Amarenco, Pierre; Brunell, Robert; Curto, Madelyn; Civeira, Fernando; Flather, Marcus; Glynn, Robert J.; Gregoire, Jean; Jukema, J. Wouter; Karpov, Yuri; Kastelein, John J.P.; Koenig, Wolfgang; Lorenzatti, Alberto; Manga, Pravin; Masiukiewicz, Urszula; Miller, Michael; Mosterd, Arend; Murin, Jan; Nicolau, Jose C.; Nissen, Steven; Ponikowski, Piotr; Santos, Raul D.; Schwartz, Pamela F.; Soran, Handrean; White, Harvey; Wright, R. Scott; Vrablik, Michal; Yunis, Carla; Shear, Charles L.; Tardif, Jean-Claude
Source: The New England Journal of Medicine. Unidade: FM
Subjects: COLESTEROL, PLACEBO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, v. 376, n. 16, p. 1527-1539, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488. Acesso em: 12 nov. 2024.
APA
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., et al. (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, 376( 16), 1527-1539. doi:10.1056/NEJMoa1701488
NLM
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 12 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Vancouver
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 12 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Artigo de periodico
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab (2017)
Ridker, Paul M.; Tardif, Jean-Claude; Amarenco, Pierre; Duggan, William; Glynn, Robert J.; Jukema, J. Wouter; Kastelein, John J.P.; Kim, Albert M.; Koenig, Wolfgang; Nissen, Steven; Revkin, James; Rose, Lynda M.; Santos, Raul D.; Schwartz, Pamela F.; Shear, Charles L.; Yunis, Carla
Source: The New England Journal of Medicine. Unidade: FM
Subjects: COLESTEROL, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, v. 376, n. 16, p. 1517-1526, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062. Acesso em: 12 nov. 2024.
APA
Ridker, P. M., Tardif, J. -C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., et al. (2017). Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine, 376( 16), 1517-1526. doi:10.1056/NEJMoa1614062
NLM
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 nov. 12 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062
Vancouver
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1517-1526.[citado 2024 nov. 12 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614062
Artigo de periodico
Effects of dalcetrapib in patients with a recent acute coronary syndrome (2012)
Schwartz, Gregory G; Olsson, Anders G; Abt, Markus; Ballantyne, Christie M; Barter, Philip J; Brumm, Jochen; Chaitman, Bernard R; Holme, Ingar M; Kallend, David; Leiter, Lawrence A; Leitersdorf, Eran; McMurray, John J. V; Mundl, Hardi; Nicholls, Stephen J; Shah, Prediman K; Tardif, Jean-Claude; Wright, R. Scott; Marin Neto, Jose Antonio
Source: The New England Journal of Medicine. Unidade: FMRP
Subjects: CORONARIOPATIA, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHWARTZ, Gregory G et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine, v. 367, n. 22, p. 2089-2099, 2012Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1206797. Acesso em: 12 nov. 2024.
APA
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., et al. (2012). Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine, 367( 22), 2089-2099. doi:10.1056/NEJMoa1206797
NLM
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, Marin Neto JA. Effects of dalcetrapib in patients with a recent acute coronary syndrome [Internet]. The New England Journal of Medicine. 2012 ; 367( 22): 2089-2099.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1056/NEJMoa1206797
Vancouver
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, Marin Neto JA. Effects of dalcetrapib in patients with a recent acute coronary syndrome [Internet]. The New England Journal of Medicine. 2012 ; 367( 22): 2089-2099.[citado 2024 nov. 12 ] Available from: https://doi.org/10.1056/NEJMoa1206797
Artigo de periodico
Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome (2009)
Schwartz, Gregory G.; Olsson, Anders G.; Ballantyne, Christie M.; Barter, Phillip J.; Holme, Ingar M.; Kallend, David; Leiter, Lawrence A.; Leitersdorf, Eran; McMurray, John J. V.; Shah, Prediman K.; Tardif, Jean-Claude; Chaitman, Bernard R.; Maddux, Regina Duttlinger; Mathieson, John; Haddad, Antonio
Source: American Heart Journal. Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES, MORBIDADE, MORTALIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHWARTZ, Gregory G. et al. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, v. 158, n. 6, p. 896-901.e3, 2009Tradução . . Acesso em: 12 nov. 2024.
APA
Schwartz, G. G., Olsson, A. G., Ballantyne, C. M., Barter, P. J., Holme, I. M., Kallend, D., et al. (2009). Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 158( 6), 896-901.e3.
NLM
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Shah PK, Tardif J-C, Chaitman BR, Maddux RD, Mathieson J, Haddad A. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal. 2009 ; 158( 6): 896-901.e3.[citado 2024 nov. 12 ]
Vancouver
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Shah PK, Tardif J-C, Chaitman BR, Maddux RD, Mathieson J, Haddad A. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal. 2009 ; 158( 6): 896-901.e3.[citado 2024 nov. 12 ]

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Indexado em